YY/T 1231-2014 English PDF (YYT1231-2014)

Delivery: 3 seconds. Download true-PDF + Invoice.
Get QUOTATION in 1-minute: Click YY/T 1231-2014
Historical versions: YY/T 1231-2014
Preview True-PDF (Reload/Scroll if blank)

YY/T 1231-2014: Creatinine test reagent kit (Method of sarcosine oxidase)
YY/T 1231-2014
YY
ICS 11.100
C 44
PHARMACEUTICAL INDUSTRY STANDARD
OF THE PEOPLE’S REPUBLIC OF CHINA
Creatinine test reagent kit
(Method of sarcosine oxidase)
ISSUED ON. JUNE 17, 2014
IMPLEMENTED ON. JULY 1, 2015
Issued by. State Food and Drug Administration
Table of Contents
Foreword ... 3 
1  Scope ... 4 
2  Normative References ... 4 
3  Requirements ... 4 
4  Test Method ... 5 
5  Labeling and Instructions for Use ... 8 
6  Packaging, Transport and Storage ... 13 
Bibliography ... 14 
Foreword 
This Standard is drafted according to the rules specified in GB/T 1.1-2009.
Please note that some contents in the Document may involve patents. The issuing
organization of this Document does not undertake the responsibility of identifying these
patents.
This Standard was proposed by State Food and Drug Administration.
This Standard shall be under the jurisdiction of National Technical Committee (SAC/TC
136) on System of Medical Clinical Test Lab and in Vitro Diagnostic System of
Standardization Administration of China.
Drafting organizations of this Standard. Beijing Institute of Medical Device Testing,
Beijing Branch of Hitachi High-Tech (Shanghai) International Trade Co., Ltd., Shanghai
Rongsheng Biology Pharmacy Co., Ltd., Merit Choice Bio-Engineering Co., Ltd., and
Abbott Trade (Shanghai) Co., Ltd.
The main drafters of this Standard. Wang Jun, Bi Chunlei, Zhang Yongmei, Zhang
Zhengqiang, Xu Donghuan, and Wang Xuefeng.
Creatinine Test Reagent Kit
(Method of sarcosine oxidase)
1  Scope 
This standard specifies the technical requirements, test method, labeling, instructions
for use, packaging, transport and storage of creatinine test reagent (kit) (method of
sarcosine oxidase).
This standard applies to the creatinine test reagent (kit) that is used to carry out
quantitative determination of the creatinine concentration in serum, plasma and urine
with the method of sarcosine oxidase. It includes manual reagent and reagents used in
semi-automatic and full-automatic biochemical analyzer.
This standard does not apply to the creatinine test reagent (kit) with picric acid method.
This standard does not apply to the dry creatinine test reagent (kit).
2  Normative References 
The following document is indispensable for the application of this Document. For dated
references, only dated edition applies to this document. For undated references, the
latest edition (including all amendments) applies to this document.
GB 3100 The international system of units and its application
GB/T 21415-2008 In vitro diagnostic medical devices - Measurement of quantities
in biological samples - Metrological traceability of values assigned to calibrators and
control materials
YY /T 0316 Medical devices - Application of risk management to medical devices
YY/T 0466.1 Medical devices - Symbols to be used with medical device labels,
labelling and information to be supplied - Part 1. General requirements
3  Requirements 
3.1 Appearance
It shall meet the normal appearance requirements specified by the manufacturer.
3.2 Installed capacity
The installed capacity of liquid reagent shall not be less than the labeled amount.
3.3 Absorbance of reagent blank
The absorbance of reagent blank shall be within the range given by the manufacturer.
3.4 Analysis sensitivity
The rate of change in absorbance shall be within the range given by the manufacturer
operation manual of the system;
m) If the detailed instructions for use is not enclosed with the reagent (kit), the
manufacturer shall ensure that the users can get the correct version of the
instructions for use;
n) The labels of external and internal packaging shall include the specified information.
The language and/or symbols used shall be easy to understand;
Example. Printing quality, font and font size.
o) The marking, labeling and instructions for use accompanying with the reagent (kit)
shall include at least the before-use safe handling and storage.
5.2 Marking and labels of external packaging
The marking and labels of external packaging shall include the following information.
a) Manufacturer's name and address;
Note 1. the address may include the province, city, county and town, when applicable;
Note 2. the name and address of the authorized representative, distributor or importer may also be
included.
b) Reagent (kit) name. Additional marking information shall be provided if the reagent
(kit) can not be identified uniquely based on the name;
c) Batch number. If the reagent (kit) contains the components in different batch number,
the batch number of the external packaging shall ensure that the batch number of
each component can be traced from the manufacturer's production records;
d) Composition, including the quality, volume, volume after re-dissolution and/or test
number;
e) Intended use. Brief instructions for the intended use shall be provided if the reagent
(kit) name does not reflect the intended use;
f) In vitro diagnostic purpose;
g) Storage and disposal conditions.
— The necessary storage conditions, which can guarantee the steady state of
reagents, calibrators and control materials under the unpacking state, shall be
provided;
— Other conditions affecting stability shall be specified;
— All other special measures taken in the case of the product disposal shall be
specified.
h) Expiration date.
— The expiration date under the storage conditions shall be specified;
— The expiration date shall be expressed in year and month; and in day when
applicable;
— If only the year and month are given, the expiration date shall be the last day of
radioactive or biological hazards), appropriate words or symbols shall be marked
on the external packaging to warn the hazards. The requirements of YY/T 0316
are applicable;
— If the in vitro diagnostic reagent contains human or animal derived substances,
the potentially infectious warning shall be given, taking into account the risk
caused by infection of infectious material and its content;
— The dangerous conditions caused by improper use, reasonably foreseeable
misuse and usage method not recommended by the manufacturer shall be
explicitly stated, when applicable. The requirements of YY/T 0316 are applicable;
— The information for safe treatment and disposal of the materials after being used
shall be provided, when applicable;
— Explicitly indicate that the reagent (kit) shall be used for one time only, when
applicable.
k) Sample collection, handling and storage.
— Special requirements for the sample’s usage, collection, pretreatment, and/or
storage conditions shall be specified;
— Special instructions for preparation shall be specified before the samples are
collected by patients.
l) Inspection procedure.
— The complete and detailed test procedures which shall be followed shall be
provided;
— All the necessary procedures for sample preparation and steps to carry out test
and gain the results shall be included;
— The dilution solution shall be provided, when applicable.
m) Control process.
— The enough information to indicate the performance of in vitro diagnostic reagent
(kit) and the correct operating methods in accordance with the instructions shall
be provided;
— If a clear suggestion for the quality control program is provided, then it shall explain
the actions needed to be taken by the user and the requirements.
n) Calculation of test...